% 0期刊文章% Tiberi,西蒙% Sotgiu, Giovanni %A D'Ambrosio, Lia %A Centis, Rosella %A Abdo Arbex, Marcos %A Alarcon Arrascue, Edith %A Alffenaar, Jan Willem %A Caminero, Jose A. %A Gaga, Mina %A Gualano, Gina %A Skrahina, Alena %A Solovic, Ivan %A Sulis, Giorgia %A Tadolini, Marina %A Alarcon Guizado, Valentina %A De Lorenzo, Saverio %A Roby Arias, Aurora Jazmín %A Scardigli, Anna %A Akkerman, Onno W. %A Aleksa, Alena %A Artsukevich, Janina %A Auchynka, Vera %A Bonini, Eduardo Henrique %A Chong Marín, Félix Antonio %A Collahuazo López, Lorena %A de Vries, Gerard %A Dore, Simone %A Kunst, Heinke %A Matteelli, Alberto %A Moschos, Charalampos %A Palmieri, Fabrizio %A Papavasileiou, Apostolos %A Payen, Marie-Christine %A Piana, Andrea %A Spanevello, Antonio %A Vargas Vasquez, Dante %A Viggiani, Pietro %A White, Veronica %A Zumla, Alimuddin %A Migliori, Giovanni Battista %T Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB %D 2016 %R 10.1183/13993003.00214-2016 %J European Respiratory Journal %P 1758-1766 %V 47 %N 6 %X No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanate versus meropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases.84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60–428) versus 85 (49–156) days, respectively.Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only.Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients.Meropenem/clavulanate is safe and more effective than imipenem/clavulanate in treating MDR and XDR-TB patients http://ow.ly/Z4S2o %U //www.qdcxjkg.com/content/erj/47/6/1758.full.pdf